Moderna just got FDA approval for its RSV vaccine — only its second product on the marketByBruce GilPublishedMay 31, 2024
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbusterByBruce GilUpdatedMay 31, 2024
Ozempic supply trackers, bird flu vaccines, and Merck's future: Pharma news roundupByBruce GilPublishedMay 31, 2024
There's a way to see what Big Pharma is paying your doctorByMatt Novak / GizmodoPublishedMay 30, 2024
Moderna's mRNA bird flu vaccine trial is close to getting U.S. government fundingByBruce GilUpdatedMay 30, 2024
Merck is spending $3 billion on an eye drug developer as it braces to lose a key cancer patentByBruce GilPublishedMay 29, 2024
Ozempic and weight loss drug shortages can now be tracked by patientsByBruce GilPublishedMay 29, 2024
Novo Nordisk says Ozempic is expensive because of America's health care systemByBruce GilPublishedMay 28, 2024
Ozempic can also help with chronic kidney disease, a study funded by Novo Nordisk findsByBruce GilUpdatedMay 24, 2024
Eli Lilly is spending billions on a new facility to make its popular weight loss drug ZepboundByBruce GilUpdatedMay 24, 2024
Ozempic knockoffs, Pfizer's cost-cutting, and AstraZeneca’s future: Pharma news roundupByBruce GilPublishedMay 24, 2024
Guardant Health's blood test to detect deadly colon cancer is under review by the FDAByBruce GilPublishedMay 23, 2024
Pfizer plans to cut costs by $1.5 billion as demand for COVID vaccine dwindlesByBruce GilPublishedMay 22, 2024
Novo Nordisk's experimental weekly insulin comes with a higher risk of low blood sugar, warns FDAByBruce GilPublishedMay 22, 2024
GSK says its experimental drug reduced asthma attacks with only two doses a yearByBruce GilPublishedMay 21, 2024
Hims & Hers is selling an Ozempic knockoff without FDA approval. Here's howByBruce GilPublishedMay 21, 2024
AstraZeneca aims increase its annual revenue by 75% in its post-COVID eraByBruce GilPublishedMay 21, 2024
